Cargando…

Prognosis of Vascular Access in Haemodialysis Patients with Autosomal Dominant Polycystic Kidney Disease

Vascular diseases are commonly observed in patients with autosomal dominant polycystic kidney disease (ADPKD). We aim to investigate the differences in the risk for arteriovenous fistula or graft (AVF/AVG) dysfunction in haemodialysis (HD) patients with and without ADPKD. 557 ADPKD and 1671 non-ADPK...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Tsung-Lun, Chen, Chun-Fan, Tan, Ann Charis, Chan, Chia-Hao, Ou, Shuo-Ming, Chen, Fan-Yu, Yu, Ko-Wen, Chen, Yung-Tai, Lin, Chih-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004976/
https://www.ncbi.nlm.nih.gov/pubmed/32029758
http://dx.doi.org/10.1038/s41598-020-58441-5
_version_ 1783494832314908672
author Lee, Tsung-Lun
Chen, Chun-Fan
Tan, Ann Charis
Chan, Chia-Hao
Ou, Shuo-Ming
Chen, Fan-Yu
Yu, Ko-Wen
Chen, Yung-Tai
Lin, Chih-Ching
author_facet Lee, Tsung-Lun
Chen, Chun-Fan
Tan, Ann Charis
Chan, Chia-Hao
Ou, Shuo-Ming
Chen, Fan-Yu
Yu, Ko-Wen
Chen, Yung-Tai
Lin, Chih-Ching
author_sort Lee, Tsung-Lun
collection PubMed
description Vascular diseases are commonly observed in patients with autosomal dominant polycystic kidney disease (ADPKD). We aim to investigate the differences in the risk for arteriovenous fistula or graft (AVF/AVG) dysfunction in haemodialysis (HD) patients with and without ADPKD. 557 ADPKD and 1671 non-ADPKD patients were enrolled in the study after propensity score matching. The primary outcome measure is the incidence rate of AVF/AVG dysfunction. The incidence rates and risks of AVF/AVG dysfunction (per 100 person-years) for ADPKD and non-ADPKD patients were (1) 38.83 and 48.99 [SHR = 0.79, P = 0.137], respectively, for within 90 days, (2) 45.85 and 51.31 [SHR = 0.90, P = 0.300], respectively, for within 180 days, (3) 44.42 and 41.40 [SHR = 1.08, P = 0.361], respectively, for within the first year, (4) 27.38 and 24.69 [SHR = 1.09, P = 0.168], respectively, for within 5 years, (5) 17.35 and 13.80 [SHR = 1.19, P = 0.045], respectively, for between the 1st and 10th year, and (6) 25.40 and 21.22 [SHR = 1.14, P = 0.031], respectively, for all periods. ADPKD patients had lower incidence rates of AVF/AVG dysfunction within the first 180 days than non-ADPKD patients, but presented a higher incidence rate after 1 year of AVF/AVG creation and onwards.
format Online
Article
Text
id pubmed-7004976
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70049762020-02-14 Prognosis of Vascular Access in Haemodialysis Patients with Autosomal Dominant Polycystic Kidney Disease Lee, Tsung-Lun Chen, Chun-Fan Tan, Ann Charis Chan, Chia-Hao Ou, Shuo-Ming Chen, Fan-Yu Yu, Ko-Wen Chen, Yung-Tai Lin, Chih-Ching Sci Rep Article Vascular diseases are commonly observed in patients with autosomal dominant polycystic kidney disease (ADPKD). We aim to investigate the differences in the risk for arteriovenous fistula or graft (AVF/AVG) dysfunction in haemodialysis (HD) patients with and without ADPKD. 557 ADPKD and 1671 non-ADPKD patients were enrolled in the study after propensity score matching. The primary outcome measure is the incidence rate of AVF/AVG dysfunction. The incidence rates and risks of AVF/AVG dysfunction (per 100 person-years) for ADPKD and non-ADPKD patients were (1) 38.83 and 48.99 [SHR = 0.79, P = 0.137], respectively, for within 90 days, (2) 45.85 and 51.31 [SHR = 0.90, P = 0.300], respectively, for within 180 days, (3) 44.42 and 41.40 [SHR = 1.08, P = 0.361], respectively, for within the first year, (4) 27.38 and 24.69 [SHR = 1.09, P = 0.168], respectively, for within 5 years, (5) 17.35 and 13.80 [SHR = 1.19, P = 0.045], respectively, for between the 1st and 10th year, and (6) 25.40 and 21.22 [SHR = 1.14, P = 0.031], respectively, for all periods. ADPKD patients had lower incidence rates of AVF/AVG dysfunction within the first 180 days than non-ADPKD patients, but presented a higher incidence rate after 1 year of AVF/AVG creation and onwards. Nature Publishing Group UK 2020-02-06 /pmc/articles/PMC7004976/ /pubmed/32029758 http://dx.doi.org/10.1038/s41598-020-58441-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Lee, Tsung-Lun
Chen, Chun-Fan
Tan, Ann Charis
Chan, Chia-Hao
Ou, Shuo-Ming
Chen, Fan-Yu
Yu, Ko-Wen
Chen, Yung-Tai
Lin, Chih-Ching
Prognosis of Vascular Access in Haemodialysis Patients with Autosomal Dominant Polycystic Kidney Disease
title Prognosis of Vascular Access in Haemodialysis Patients with Autosomal Dominant Polycystic Kidney Disease
title_full Prognosis of Vascular Access in Haemodialysis Patients with Autosomal Dominant Polycystic Kidney Disease
title_fullStr Prognosis of Vascular Access in Haemodialysis Patients with Autosomal Dominant Polycystic Kidney Disease
title_full_unstemmed Prognosis of Vascular Access in Haemodialysis Patients with Autosomal Dominant Polycystic Kidney Disease
title_short Prognosis of Vascular Access in Haemodialysis Patients with Autosomal Dominant Polycystic Kidney Disease
title_sort prognosis of vascular access in haemodialysis patients with autosomal dominant polycystic kidney disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004976/
https://www.ncbi.nlm.nih.gov/pubmed/32029758
http://dx.doi.org/10.1038/s41598-020-58441-5
work_keys_str_mv AT leetsunglun prognosisofvascularaccessinhaemodialysispatientswithautosomaldominantpolycystickidneydisease
AT chenchunfan prognosisofvascularaccessinhaemodialysispatientswithautosomaldominantpolycystickidneydisease
AT tananncharis prognosisofvascularaccessinhaemodialysispatientswithautosomaldominantpolycystickidneydisease
AT chanchiahao prognosisofvascularaccessinhaemodialysispatientswithautosomaldominantpolycystickidneydisease
AT oushuoming prognosisofvascularaccessinhaemodialysispatientswithautosomaldominantpolycystickidneydisease
AT chenfanyu prognosisofvascularaccessinhaemodialysispatientswithautosomaldominantpolycystickidneydisease
AT yukowen prognosisofvascularaccessinhaemodialysispatientswithautosomaldominantpolycystickidneydisease
AT chenyungtai prognosisofvascularaccessinhaemodialysispatientswithautosomaldominantpolycystickidneydisease
AT linchihching prognosisofvascularaccessinhaemodialysispatientswithautosomaldominantpolycystickidneydisease